Effect of paroxetine treatment on glycaemic control and quality of life in mildly depressed type two diabetic subjects: a double-blind randomised placebo controlled six month trial
Completed
- Conditions
- Type two diabetes mellitus and depression.Nutritional, Metabolic, Endocrine
- Registration Number
- ISRCTN55819922
- Lead Sponsor
- GlaxoSmithKline (Finland)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 38
Inclusion Criteria
1. Volunteers between 50 and 70 years of age
2. Diagnosed type two diabetes
3. Hba1c more than 7.0%
4. Mild symptoms of depression
Exclusion Criteria
1. Moderate to severe depression based on Diagnostic and Statistical Manual of mental disorders (DSM-IV) criteria
2. Severe diabetic complications
3. Use of warfarin
4. Glaucoma
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 10% decrease in HbA1c.
- Secondary Outcome Measures
Name Time Method 20% improvement in quality of life as defined by the RAND-36 health relate quality of life questionnaire.